Skip to main content
ANVS logo

ANVS · Annovis Bio, Inc.

Track ANVS — free
$1.82 +0.03 (+1.68%) At close · Aug 21
Market Cap
$76.27M
Shares
42.61M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.82 Open$1.78 Day$1.77–1.84 52W close$1.59–5.10 Avg vol 30d624K Short int5.2M · 12.2% float · 9.5d Short vol59% Last earningsAug 12, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −27%
below
Price vs 50-day avg +1%
above
RSI (14) 51
neutral
MACD trend Positive
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +10%
trailing
6-month return −32%
trailing
YTD return −47%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.19% of float · ▼ -4.7% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
EPS growth +39%
Y/Y
Balance sheet $19.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −69%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−27% Bearish
Price vs 50-day avg
+1% Bullish
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.19% of float · ▼ -4.7% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 7% Range high $5
vs 200-day avg -27% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Parkinson's disease (PD) open-label extension (OLE) study enrollment 266 Q2 2026
Pivotal Phase 3 Alzheimer's disease (AD) trial enrollment 850 Q2 2026
granted patents 40 year-end 2025
patent applications 48 year-end 2025

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANVS
Annovis Bio, Inc.
this stock
$76.27M -47.4% 12.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
$136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$86.39B +7.1% +20.8% 20.8 3.3%
ARGX
Argenx SE
$64.56B +23.6% 2.1%
CSLLY
Csl Ltd
$58.31B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
63
% held
28.3%
Net QoQ
+6.8M sh
Top holder
Empery Asset Management,…
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Falling
Shares short
5.2M
Days to cover
9.5d
Change
-257.3K sh
View
Short Volume
Short vol %
59%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
4.9K
Value
$8.3K
As of
Jul 21, 2026
View
Off-Exchange
Off-exchange %
42.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-28.9M
EPS diluted
$-1.40
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
14
View
Proposed Sales
Value
$14.8K
Shares
7.1K
Filed
Apr 2, 2026
View
Exempt Offerings
Offering
$1.1M
Filed
Apr 25, 2023
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2025
View

Performance

5D 20D 120D MTD YTD
ANVS -1.6% +9.6% -31.8% +4.0% -47.4%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +0.3% +6.3% -43.0% +1.9% -59.2%
Key facts CIK 1477845 CUSIP 03615A108 13F (30d) 59 filings 58 filers Visit website Investor relations